Side-by-side comparison of AI visibility scores, market position, and capabilities
Seres Therapeutics develops microbiome therapeutics, including Vowst, the first FDA-approved oral microbiome medicine for preventing recurrent C. difficile infection.
Seres Therapeutics is a publicly traded clinical-stage biopharmaceutical company founded in 2012 that pioneered the development of microbiome therapeutics, medicines derived from human gut microbiota. The company's lead product Vowst received FDA approval in 2023 as the first oral microbiome therapeutic, consisting of purified fecal microbiota spores administered as capsules to prevent recurrent Clostridioides difficile infection after antibiotic treatment. C. difficile infects hundreds of thousands of Americans annually and has high recurrence rates that existing antibiotics cannot fully prevent. Vowst works by restoring a diverse, healthy gut microbiome that can resist C. difficile colonization. Seres has partnered with Nestlé Health Science for US commercialization and is developing pipeline programs for inflammatory bowel disease, oncology supportive care, and other conditions where the gut microbiome plays a pathological role. The company's success with Vowst validated the regulatory pathway for microbiome therapeutics and established Seres as the pioneer of an emerging therapeutic class with broad potential across gastrointestinal and systemic diseases.
Raised $115M (Feb 2026) led by General Atlantic. Post-merger with Soli Organic creates largest indoor farm in North America. ~$200M combined first-year revenues.
80 Acres Farms is a commercial-scale indoor vertical farming company that, following its merger with Soli Organic, operates the largest indoor farming network in North America. The company raised $115 million in February 2026 led by General Atlantic, with projected first-year combined revenues approaching $200 million — making it one of the few vertical farming companies to achieve genuine commercial scale after years of industry attrition that eliminated several high-profile competitors.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.